share_log

EF Hutton Maintains Buy on CARISMA Therapeutics, Maintains $24 Price Target

EF Hutton Maintains Buy on CARISMA Therapeutics, Maintains $24 Price Target

EF Hutton維持對CARISMA Therapeutics的買入評級,維持24美元的目標價
Benzinga ·  11/07 05:32

EF Hutton analyst Jason Kolbert maintains CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $24 price target.

EF Hutton分析師Jason Kolbert維持CARISMA Therapeutics(納斯達克:CARM)的買入評級,維持24美元的目標價

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論